[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422220":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":51,"centralContacts":55,"locations":61,"responsibleParty":362,"collaborators":42,"id":364,"slug":365,"hasResults":366,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":42,"eligibilityCriteria":370,"healthyVolunteers":366,"sex":371,"minAge":372,"maxAge":42,"enrollmentInfo":373,"targetDuration":42,"studyType":376,"phases":377,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":64,"whyStopped":42,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},{"fullName":5,"class":6},"Calico Life Sciences LLC","INDUSTRY",[8,14,19,23,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Escalation","EXPERIMENTAL","ABBV-CLS-484 will be administered as a monotherapy in subjects with solid tumors",[13],"Drug: ABBV-CLS-484",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination Dose Escalation with PD-1 Inhibitor","ABBV-CLS-484 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors",[13,18],"Drug: Programmed Cell Death-1 (PD-1) Inhibitor",{"label":20,"type":10,"description":21,"interventionNames":22},"Monotherapy Expansion","ABBV-CLS-484 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC)",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Combination Expansion with PD-1 Inhibitor","ABBV-CLS-484 will be administered at the determined recommended dose in combination with Programmed Cell Death-1 Inhibitor in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1\u002FPD-L1, and advanced ccRCC.",[13,27],"Drug: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)",{"label":29,"type":10,"description":30,"interventionNames":31},"Combination Dose Escalation with VEGFR TKI","ABBV-CLS-484 will be administered in combination with a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) in subjects with solid tumors",[13,18],{"label":33,"type":10,"description":34,"interventionNames":35},"Combination Expansion","ABBV-CLS-484 will be administered at the determined recommended dose in combination with VEGFR TKI in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1\u002FPD-L1, and advanced ccRCC.",[13,27],[37,43,47],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","ABBV-CLS-484","Oral Capsule",[15,29,33,24,9,20],null,{"type":38,"name":44,"description":45,"armGroupLabels":46,"otherNames":42},"Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)","Oral Tablet",[33,24],{"type":38,"name":48,"description":49,"armGroupLabels":50,"otherNames":42},"Programmed Cell Death-1 (PD-1) Inhibitor","Intravenous (IV) infusion",[15,29],[52],{"name":5,"affiliation":53,"role":54},"Calico","STUDY_DIRECTOR",[56],{"name":57,"role":58,"phone":59,"phoneExt":42,"email":60},"Nicole Director Clinical Operations","CONTACT","650-754-6200","info@calicolabs.com",[62,76,86,100,110,116,126,138,151,161,174,183,193,203,215,224,236,246,256,265,277,286,296,303,312,323,329,335,347,356],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":42},"University of Arizona Cancer Center - Tucson \u002FID# 262698","RECRUITING","Tucson","Arizona","85724","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-110.92648,32.22174,{"lat":74,"lon":73},{"facility":77,"status":64,"city":78,"state":79,"zip":80,"country":68,"countryCode":69,"cosmosGeoPoint":81,"geoPoint":85,"contacts":42},"Yale University School of Medicine \u002FID# 225707","New Haven","Connecticut","06510",{"type":71,"coordinates":82},[83,84],-72.92816,41.30815,{"lat":84,"lon":83},{"facility":87,"status":64,"city":88,"state":89,"zip":90,"country":68,"countryCode":69,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Johns Hopkins Hospital \u002FID# 254056","Baltimore","Maryland","21287",{"type":71,"coordinates":92},[93,94],-76.61219,39.29038,{"lat":94,"lon":93},[97],{"name":98,"role":58,"phone":99,"phoneExt":42,"email":42},"Site Coordinator","443-287-8312",{"facility":101,"status":64,"city":102,"state":103,"zip":104,"country":68,"countryCode":69,"cosmosGeoPoint":105,"geoPoint":109,"contacts":42},"Beth Israel Deaconess Medical Center \u002FID# 252009","Boston","Massachusetts","02215-5400",{"type":71,"coordinates":106},[107,108],-71.05977,42.35843,{"lat":108,"lon":107},{"facility":111,"status":64,"city":102,"state":103,"zip":112,"country":68,"countryCode":69,"cosmosGeoPoint":113,"geoPoint":115,"contacts":42},"Dana-Farber Cancer Institute \u002FID# 249642","02215",{"type":71,"coordinates":114},[107,108],{"lat":108,"lon":107},{"facility":117,"status":64,"city":118,"state":119,"zip":120,"country":68,"countryCode":69,"cosmosGeoPoint":121,"geoPoint":125,"contacts":42},"University of Michigan Comprehensive Cancer Center Michigan Medicine \u002FID# 252010","Ann Arbor","Michigan","48109",{"type":71,"coordinates":122},[123,124],-83.74088,42.27756,{"lat":124,"lon":123},{"facility":127,"status":64,"city":128,"state":128,"zip":129,"country":68,"countryCode":69,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"NYU Laura and Isaac Perlmutter Cancer Center - 34th Street \u002FID# 257869","New York","10016",{"type":71,"coordinates":131},[132,133],-74.00597,40.71427,{"lat":133,"lon":132},[136],{"name":98,"role":58,"phone":137,"phoneExt":42,"email":42},"(212)-731-6230",{"facility":139,"status":64,"city":140,"state":141,"zip":142,"country":68,"countryCode":69,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Duke Cancer Center \u002FID# 251975","Durham","North Carolina","27710",{"type":71,"coordinates":144},[145,146],-78.89862,35.99403,{"lat":146,"lon":145},[149],{"name":98,"role":58,"phone":150,"phoneExt":42,"email":42},"(919) 681-7460",{"facility":152,"status":153,"city":154,"state":141,"zip":155,"country":68,"countryCode":69,"cosmosGeoPoint":156,"geoPoint":160,"contacts":42},"Carolina BioOncology Institute \u002FID# 225704","COMPLETED","Huntersville","28078",{"type":71,"coordinates":157},[158,159],-80.84285,35.41069,{"lat":159,"lon":158},{"facility":162,"status":64,"city":163,"state":164,"zip":165,"country":68,"countryCode":69,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Perelman Center for Advanced Medicine \u002FID# 250188","Philadelphia","Pennsylvania","19104",{"type":71,"coordinates":167},[168,169],-75.16362,39.95238,{"lat":169,"lon":168},[172],{"name":98,"role":58,"phone":173,"phoneExt":42,"email":42},"(215) 316-5151",{"facility":175,"status":64,"city":176,"state":164,"zip":177,"country":68,"countryCode":69,"cosmosGeoPoint":178,"geoPoint":182,"contacts":42},"UPMC Hillman Cancer Ctr \u002FID# 225706","Pittsburgh","15232",{"type":71,"coordinates":179},[180,181],-79.99589,40.44062,{"lat":181,"lon":180},{"facility":184,"status":64,"city":185,"state":186,"zip":187,"country":68,"countryCode":69,"cosmosGeoPoint":188,"geoPoint":192,"contacts":42},"Lifespan Cancer Institute at Rhode Island Hospital \u002FID# 225705","Providence","Rhode Island","02903-4923",{"type":71,"coordinates":189},[190,191],-71.41283,41.82399,{"lat":191,"lon":190},{"facility":194,"status":64,"city":195,"state":196,"zip":197,"country":68,"countryCode":69,"cosmosGeoPoint":198,"geoPoint":202,"contacts":42},"University of Texas Southwestern Medical Center \u002FID# 251974","Dallas","Texas","75390-7208",{"type":71,"coordinates":199},[200,201],-96.80667,32.78306,{"lat":201,"lon":200},{"facility":204,"status":64,"city":205,"state":196,"zip":206,"country":68,"countryCode":69,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"University of Texas MD Anderson Cancer Center \u002FID# 252004","Houston","77030",{"type":71,"coordinates":208},[209,210],-95.36327,29.76328,{"lat":210,"lon":209},[213],{"name":98,"role":58,"phone":214,"phoneExt":42,"email":42},"713-792-2121",{"facility":216,"status":153,"city":217,"state":196,"zip":218,"country":68,"countryCode":69,"cosmosGeoPoint":219,"geoPoint":223,"contacts":42},"NEXT Oncology \u002FID# 225708","San Antonio","78229",{"type":71,"coordinates":220},[221,222],-98.49363,29.42412,{"lat":222,"lon":221},{"facility":225,"status":64,"city":226,"state":227,"zip":228,"country":229,"countryCode":230,"cosmosGeoPoint":231,"geoPoint":235,"contacts":42},"Institut Paoli-Calmettes \u002FID# 260956","Marseille","Bouches-du-Rhone","13009","France","FR",{"type":71,"coordinates":232},[233,234],5.38107,43.29695,{"lat":234,"lon":233},{"facility":237,"status":64,"city":238,"state":239,"zip":240,"country":229,"countryCode":230,"cosmosGeoPoint":241,"geoPoint":245,"contacts":42},"IUCT Oncopole \u002FID# 252673","Toulouse","Occitanie","31059",{"type":71,"coordinates":242},[243,244],1.44367,43.60426,{"lat":244,"lon":243},{"facility":247,"status":64,"city":248,"state":249,"zip":250,"country":229,"countryCode":230,"cosmosGeoPoint":251,"geoPoint":255,"contacts":42},"Centre Antoine-Lacassagne \u002FID# 252606","Nice","Provence-Alpes-Côte d'Azur Region","06189",{"type":71,"coordinates":252},[253,254],7.26608,43.70313,{"lat":254,"lon":253},{"facility":257,"status":64,"city":258,"state":42,"zip":259,"country":229,"countryCode":230,"cosmosGeoPoint":260,"geoPoint":264,"contacts":42},"Hopital Foch \u002FID# 252607","Suresnes","92151",{"type":71,"coordinates":261},[262,263],2.22929,48.87143,{"lat":263,"lon":262},{"facility":266,"status":64,"city":267,"state":268,"zip":269,"country":270,"countryCode":271,"cosmosGeoPoint":272,"geoPoint":276,"contacts":42},"Rabin Medical Center \u002FID# 263631","Petah Tikva","Central District","4941492","Israel","IL",{"type":71,"coordinates":273},[274,275],34.88747,32.08707,{"lat":275,"lon":274},{"facility":278,"status":64,"city":279,"state":279,"zip":280,"country":270,"countryCode":271,"cosmosGeoPoint":281,"geoPoint":285,"contacts":42},"Hadassah Medical Center \u002FID# 252366","Jerusalem","91120",{"type":71,"coordinates":282},[283,284],35.21633,31.76904,{"lat":284,"lon":283},{"facility":287,"status":64,"city":288,"state":289,"zip":290,"country":270,"countryCode":271,"cosmosGeoPoint":291,"geoPoint":295,"contacts":42},"The Chaim Sheba Medical Center \u002FID# 226756","Ramat Gan","Tel Aviv","5265601",{"type":71,"coordinates":292},[293,294],34.81065,32.08227,{"lat":294,"lon":293},{"facility":297,"status":64,"city":298,"state":299,"zip":300,"country":301,"countryCode":302,"cosmosGeoPoint":42,"geoPoint":42,"contacts":42},"National Cancer Center Hospital \u002FID# 225884","Chuo-ku","Tokyo","104-0045","Japan","JP",{"facility":304,"status":64,"city":305,"state":305,"zip":306,"country":301,"countryCode":302,"cosmosGeoPoint":307,"geoPoint":311,"contacts":42},"Wakayama Medical University Hospital \u002FID# 252988","Wakayama","641-8510",{"type":71,"coordinates":308},[309,310],135.16667,34.23333,{"lat":310,"lon":309},{"facility":313,"status":64,"city":314,"state":315,"zip":316,"country":317,"countryCode":42,"cosmosGeoPoint":318,"geoPoint":322,"contacts":42},"Seoul National University Hospital \u002FID# 254635","Seoul","Seoul Teugbyeolsi","03080","South Korea",{"type":71,"coordinates":319},[320,321],126.9784,37.566,{"lat":321,"lon":320},{"facility":324,"status":64,"city":314,"state":315,"zip":325,"country":317,"countryCode":42,"cosmosGeoPoint":326,"geoPoint":328,"contacts":42},"Samsung Medical Center \u002FID# 260664","06351",{"type":71,"coordinates":327},[320,321],{"lat":321,"lon":320},{"facility":330,"status":64,"city":314,"state":42,"zip":331,"country":317,"countryCode":42,"cosmosGeoPoint":332,"geoPoint":334,"contacts":42},"Yonsei University Health System Severance Hospital \u002FID# 260665","03722",{"type":71,"coordinates":333},[320,321],{"lat":321,"lon":320},{"facility":336,"status":64,"city":337,"state":338,"zip":339,"country":340,"countryCode":341,"cosmosGeoPoint":342,"geoPoint":346,"contacts":42},"Institut Català d'Oncologia (ICO) - L'Hospitalet \u002FID# 252524","L'Hospitalet de Llobregat","Barcelona","08907","Spain","ES",{"type":71,"coordinates":343},[344,345],2.10028,41.35967,{"lat":345,"lon":344},{"facility":348,"status":64,"city":349,"state":349,"zip":350,"country":340,"countryCode":341,"cosmosGeoPoint":351,"geoPoint":355,"contacts":42},"Hospital Universitario 12 de Octubre \u002FID# 257374","Madrid","28041",{"type":71,"coordinates":352},[353,354],-3.70256,40.4165,{"lat":354,"lon":353},{"facility":357,"status":64,"city":349,"state":349,"zip":358,"country":340,"countryCode":341,"cosmosGeoPoint":359,"geoPoint":361,"contacts":42},"Hospital Universitario HM Sanchinarro \u002FID# 228034","28050",{"type":71,"coordinates":360},[353,354],{"lat":354,"lon":353},{"type":363,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100422220","phase-1-study-with-abbv-cls-484-in-participants-with-locally-advanced-or-metastatic-tumors-100422220",false,"NCT04777994","Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors","Inclusion Criteria:\n\n* Must weigh at least 35 kilograms (kg).\n* An Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C= 2.\n* Life expectancy of \\>= 12 weeks.\n* Laboratory values meeting protocol criteria.\n* QT interval corrected for heart rate \\\u003C 470 msec (using Fridericia's correction), and no clinically significant electrocardiographic findings.\n* Measurable disease defined by RECIST 1.1 criteria.\n\nFor Monotherapy and Combination Dose Escalation:\n\n* Participants with histologically or cytologically proven metastatic or locally advanced tumors, for which no effective standard therapy exists, or where standard therapy has failed. Participants must have received at least 1 prior systemic anticancer therapy for the indication being considered.\n\nFor Monotherapy Dose Expansion only:\n\n* Participants must have received at least 1 prior line containing PD-1\u002FPD-L1 targeted therapy with a best response by RECIST v1.1 of CR\u002FPR\u002Fstable (any duration) or stable disease (for greater than 6 months); AND\n* Must have been previously treated with 1 or more prior lines of therapy in the locally advanced or metastatic setting with the following tumor types:\n\n  * Relapsed\u002Frefractory HNSCC\n  * Relapsed\u002Frefractory NSCLC\n  * Advanced ccRCC\n\nFor PD-1 Targeting Agent Combination Dose Expansion only:\n\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1\u002FPD-L1 targeted therapy with response by RECIST v1.1 of CR\u002FPR (any duration) or stable disease (for greater than 6 months):\n\n  * Relapsed HNSCC\n  * Relapsed NSCLC\n  * Relapsed Advanced ccRCC\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1\u002FPD-L1 targeted therapy and have had disease progression with PD-1\u002FPD-L1 targeted therapy:\n\n  * Locally Advanced or metastatic MSI-H tumors\n\nFor VEGFR TKI Combination Dose Expansion only:\n\n* Relapsed advance ccRCC with no more than 1 prior VEGFR TKI\n* Participants no recent history of hemorrhage, including hemoptysis, hematemesis, or melena\n* Participants with poorly controlled hypertension are excluded.\n\nExclusion Criteria:\n\n* Untreated brain or meningeal metastases (i.e., subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 28 days after definitive therapy)\n* Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.\n* Unresolved Grade 2 or higher peripheral neuropathy.\n* History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.\n* Recent history (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis, or clinically significant pericardial effusion or arrythmia.\n* Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease.\n* History of clinically significant medical and\u002For psychiatric conditions or any other reason that, in the opinion of the investigator, would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.\n* History of uncontrolled, clinically significant endocrinopathy.\n* Known gastrointestinal disorders making absorption of oral medications problematic; subject must be able to swallow capsules.\n* If treated with a PD-1\u002FaPD-L1 targeting or other immune-oncology agents in the past, excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity, hypersensitivity to administered drug or drug related toxicity requiring discontinuation.\n* Active autoimmune disease requiring systemic treatment in past 2-years (exceptions for endocrinopathies, vitiligo or atopic conditions).\n* History of solid organ transplant or allogeneic stem cell transplant.\n* History of other malignancy, with the following exceptions:\n\n  * No known active disease present within \\>= 3 years before first dose of study treatment and felt to be at low recurrence by investigator.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* History of interstitial lung disease or pneumonitis.\n* Major surgery \\\u003C= 28 days prior to first dose of study drug\n* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local testing practices.","ALL","18 Years",{"count":374,"type":375},248,"ESTIMATED","INTERVENTIONAL",[378],"PHASE1","The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).\n\nThe trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy).\n\nPart 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors.\n\nPart 2, ABBV-CLS-484 will be administered at escalating dose levels in combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors.\n\nPart 3, ABBV-CLS-484 will be administered alone as a monotherapy at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1 targeting or with a VEGFR TKI agent in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1\u002FPD-L1, and advanced ccRCC.",[381],"Advanced Solid Tumor Cancer",[383,384,385,39,386,387,388,389,390,44],"Cancer","Tumor","anti-PD-1","clear cell renal cell carcinoma (ccRCC)","head and neck squamous cell carcinoma (HNSCC)","non-small cell lung cancer (NSCLC)","relapsed or refractory (R\u002FR)","Microsatellite instability - high tumors (MSI-H)","2026-06-02",{"date":393,"type":394},"2026-06-04","ACTUAL",{"date":396,"type":394},"2021-03-09",{"date":398,"type":375},"2026-10",{"name":5,"class":6},30]